Growth hormone deficiency expert roundtable
Watch experts discuss continuing challenges and expanding treatment options in growth hormone deficiency (GHD), led by Professor Mehul Dattani from Great Ormond Street Hospital for Children in London, UK.
In this roundtable:
- Long-acting GH in trials and the clinic
- GH in the real world: Adherence and shared decision-making
- GH biosimilars and treatment access
- Best practice for GHD diagnosis and treatment
- Challenges and uncertainties in paediatric GHD
- Panel discussion: Diagnostic thresholds, optimal GH dose and high-risk groups
What’s the latest in GH treatments? Consultant paediatrician Dr Shankar Kanumakala (NHS University Hospitals Sussex, UK) leads discussions on current options, including long-acting GH in trials and clinical practice. View transcript.
Consultant endocrinologist Dr Charlotte Höybye (Karolinska Institute, Stockholm, Sweden) takes a look at real-world GH data, including treatment adherence, and considers shared decision-making and the role of patient choice. View transcript.
Health economist Professor Steven Simoens (KU Leuven, Belgium) leads discussions on the role of biosimilars in managing GHD, including their uptake in clinical practice and the influence of injection devices. View transcript.
Is there a consensus on the optimal test for GHD? Consultant endocrinologist Dr Robert Murray (Leeds Teaching Hospitals NHS Trust, UK) considers when and how to test, the impact of obesity, and treatment goals and monitoring. View transcript.
Get an overview of GHD from Professor Mehul Dattani, including challenges and continuing uncertainties, sex disparities in diagnosis, and sex-steroid priming in GH testing. View transcript.
The panel explores topics including optimal GH dose, GH safety in high-risk subgroups, anti-GH antibodies and diagnostic thresholds in provocative GH testing. View transcript.
Meet the faculty
Professor Mehul Dattani
Mehul Dattani is Professor of Paediatric Endocrinology at the University College London (UCL) Great Ormond Street Institute of Child Health, UK, and specialty lead in endocrinology at Great Ormond Street Hospital for Children (GOSH). He has a laboratory group investigating the molecular basis of hypothalamo-pituitary disease at UCL, working on novel genes implicated in hypothalamo-pituitary development in patients with congenital hypopituitarism and the molecular basis of a paediatric brain tumour called adamantinomatous craniopharyngioma.
Disclosures
Professor Dattani was among the faculty of the Henning Andersen course sponsored by Novo Nordisk. He is on the steering committee for Pfizer PROGRES Registry and steering committee for EDGE and IDEE meetings – Sandoz. He has received lecture honoraria from Merck Serono, Novo Nordisk, Pfizer, and Sandoz. He has served on consultancy/advisory boards for Ferring, Pfizer, and Sandoz, and a Neurocrine Biosciences clinical trial contract with GOSH.
Dr Shankar Kanumakala
Shankar Kanumakala is a consultant paediatrician at NHS University Hospitals Sussex, UK. He specialises in growth, puberty and other hormone-related problems and also diabetes, particularly non-type 1 diabetes. His other areas of special interest include childhood obesity and lipid problems in children.
Disclosures
Dr Kanumakala has received a speaker honorarium from Sandoz and financial assistance to attend medical conferences from Ferring, Novo Nordisk, and Sandoz.
Dr Charlotte Höybye
Charlotte Höybye has been an associate professor in endocrinology at the Karolinska Institute, Stockholm, Sweden, since 2007, senior consultant in endocrinology since 2008 and was head of the department’s pituitary section from 2004 to 2017. Since 2010, she has been head of the Expert Group for Treatment of Endocrine Diseases, The Drug and Therapeutic Committee, Stockholm Region. She is also a healthcare professional representative for Karolinska University Hospital in the EU’s programme on Rare Endocrine diseases (EndoERN). Dr Höybye’s main clinical and research interests are within the field of pituitary and hypothalamic diseases, and she has been treating adults with growth hormone deficiency since the 1990s.
Disclosures
Dr Höybye has acted as an investigator for Novo Nordisk, Pfizer, and Sandoz. She has received lecture fees from Novo Nordisk, Pfizer, and Sandoz, and was a member of the global steering committee for the PATRO Adults study.
Professor Steven Simoens
Steven Simoens is a senior full professor of health economics at KU Leuven, Belgium. He is a founding member of the KU Leuven MABEL and PROMISE Funds – industry-sponsored but independent research funds investigating market access of biosimilar and personalised medicines, respectively. He is co-chair of the key project of the ISPOR Special Interest Group on Biosimilars.
Professor Simoens’ research and teaching interests focus on health economic aspects of medicinal products, including economic evaluations, budget impact analyses and market access policies. He has a particular interest in oncology drugs, orphan drugs, generics and biosimilars, vaccines, antibiotics, and cell and gene therapies.
Disclosures
Professor Simoens has participated in advisory boards and sponsored roundtables for, or received speakers’ fees, from Amgen, Celltrion, MSD, Organon, and Pfizer. He has contributed to studies funded by Celltrion, Hospira, Mundipharma, Organon, and Pfizer.
Professor Simoens has also received research funding from diverse partners, including the Belgian Health Care Knowledge Centre, the Belgian King Baudouin Foundation, the Foundation Scientific Research Flanders, and the Belgian National Institute for Health and Disability Insurance.
Dr Robert Murray
Robert Murray is a consultant endocrinologist and honorary associate professor at Leeds Teaching Hospitals NHS Trust, UK, having been appointed in 2004 as a full-time clinician. His subspecialty interests, both clinically and research, lie in pituitary disease, late-endocrine effects of cancer and optimising hormone replacement therapies. Dr Murray and his team have an active research programme to improve our knowledge and treatment of patients with pituitary disease.
Disclosures
Dr Murray receives research funding from Diurnal, Ipsen, and Pfizer. He has received lecture fees from Consilient Pharma, Ipsen, and Pfizer.
This content has been developed independently by Medthority who previously received educational funding from Sandoz in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
of interest
are looking at
saved
next event